Advertisement

Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy

  • Tiago Cordeiro FelisminoEmail author
  • Audrey Cabral Ferreira de Oliveira
  • Ana Caroline Fonseca Alves
  • Wilson Luiz da Costa Junior
  • Felipe José Fernadez Coimbra
  • Maria Dirlei Ferreira de Souza Begnami
  • Rachel P. Riechelmann
  • Victor Hugo Fonseca de Jesus
  • Celso Abdon Lopes de Mello
Original Research
  • 23 Downloads

Abstract

Background

Esophagogastric cancer (EGC) is a leading neoplasm worldwide. Perioperative chemotherapy (periCT) is currently a standard of care for most patients (pts). Prevalence of esophagogastric junction (EGJ) tumors is increasing over the last years.

Methods

The aim of this study was to retrospectively search for prognostic factors in pts. with locally advanced EGC treated with periCT. Three-year overall survival (OS) and Event-Free Survival (EFS) were main end-points. HER-2 positive tumors were defined by immunohistochemistry or FISH.

Results

Between June/2007 and November/2015, 128 pts. started periCT for esophagogastric junction (EGJ) or gastric adenocarcinoma (GC). Median age was 59.5 y and 64% were male. Primary site was EGJ in 27% and 65% were cN+. Diffuse subtype was seen in 42%. Ninety-seven pts. were assessed for HER-2; 14 (14.4%) were positive. After median follow-up time of 45 m, 48 deaths occurred. The 3-year OS and EFS rate was 61.3% and 51.2%, respectively. Main prognostic factors were: AJCC ypT3-T4yN1-N3 (HR 6.75 p 0.002) and EGJ primary (HR 2.64, p 0.004). Overall HER-2 was not prognostic. Still, a difference in 3-year OS was observed for GC/HER2+ compared to EGJ/HER2+ (88.9% versus 20%, p = 0.002). This difference is greater for 3-year EFS with no patient with EGJ/HER2+ free-of-event against 62.5% for GC/HER+ (p = 0.011).

Conclusion

In our analysis, pathological staging and primary site were main prognostic factors. Moreover, a small group of EGJ/HER2+ had very poor survival.

Keywords

Gastric cancer Gastroespohageal junction Chemotherapy HER2 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.CrossRefGoogle Scholar
  2. 2.
    Al-Batran S, Lorenzen S. Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? Hematol Oncol Clin North Am. 2013;31:441–52.CrossRefGoogle Scholar
  3. 3.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefGoogle Scholar
  4. 4.
    Cunningham D, Allum WH, Stenning SP, Allum WH, Stenning SP, Thompson JN, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefGoogle Scholar
  5. 5.
    Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefGoogle Scholar
  6. 6.
    Al Batran S-E, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial (abstract). J Clin Oncol 2017 (suppl; abstr 4004).Google Scholar
  7. 7.
    Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass J, Bennett CL, et al. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003;134:720–7.CrossRefGoogle Scholar
  8. 8.
    Bruno L, Nesi G, Montinaro F, Carassale G, Lassig R, Boddi V, et al. Clinicopathologic findings and results of surgical treatment in cardiac adenocarcinoma. J Surg Oncol. 2000;74:33–5.CrossRefGoogle Scholar
  9. 9.
    Costa L, Toneto M, Moreira L. Do proximal and distal gastric turmors behave differently? Arquivos Brasileiros de Cirurgia Digestiva:ABCD. 2016;29:232–5.CrossRefGoogle Scholar
  10. 10.
    Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.CrossRefGoogle Scholar
  11. 11.
    Ajani JA, In H, Sano T, et al. Stomach. In: Amin MB, editor. AJCC cancer staging manual, 8th. Chicago: AJCC; 2017. p. 203.CrossRefGoogle Scholar
  12. 12.
    Smyth E, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol. 2016;34:2721–7.CrossRefGoogle Scholar
  13. 13.
    Marchet A, Mocellin S, Ambrosi A, de Manzoni G, Di Leo A, Marrelli D, et al. The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol. 2008;34:159–65.CrossRefGoogle Scholar
  14. 14.
    Han DS, Suh YS, Kong SH, Lee HJ, Choi Y, Aikou S, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012;30:3834–40.CrossRefGoogle Scholar
  15. 15.
    Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23:4441–9.CrossRefGoogle Scholar
  16. 16.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefGoogle Scholar
  17. 17.
    Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer. 2012;130:2845–56.CrossRefGoogle Scholar
  18. 18.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York: Springer; 2010.Google Scholar
  19. 19.
    Kattan M, Karpeh M, Mazumdar M, Brennan M. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647–50.CrossRefGoogle Scholar
  20. 20.
    Schmidt T, Sicic L, Blank S, Becker K, Weichert W. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer. 2014;110:1712–20.CrossRefGoogle Scholar
  21. 21.
    Siewert J, MD FM, Werner M, Stein H. Adenocarcinoma of the esophagogastric junction results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353–61.CrossRefGoogle Scholar
  22. 22.
    Amin, MB, Edge, S, Greene, F, Byrd, DR, Brookland, RK, Washington, MK, et al. AJCC cancer staging manual (8th edition). Springer international publishing: American joint commission on Cancer; 2017.Google Scholar
  23. 23.
    Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246:1–8.CrossRefGoogle Scholar
  24. 24.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. CROSS group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;31(366):2074–84.CrossRefGoogle Scholar
  25. 25.
    Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer. 2017;81:183–90.CrossRefGoogle Scholar
  26. 26.
    Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27:660–7.CrossRefGoogle Scholar
  27. 27.
    Al-Batran S, Pauligk C, Homann N, et al. Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Presented at: ESMO 2017 congress; Madrid, Spain: September 8–12, 2017. Abstract LBA27.Google Scholar
  28. 28.
    Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754–61.CrossRefGoogle Scholar
  29. 29.
    Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2013;24:1253–61.CrossRefGoogle Scholar
  30. 30.
    Maresch J, Schoppmann S, Thallinger C, Zielinski C, et al. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol. 2012;82:310–22.CrossRefGoogle Scholar
  31. 31.
    Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.CrossRefGoogle Scholar
  32. 32.
    Begnami MD, Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29:3030–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Tiago Cordeiro Felismino
    • 1
    Email author
  • Audrey Cabral Ferreira de Oliveira
    • 1
  • Ana Caroline Fonseca Alves
    • 1
  • Wilson Luiz da Costa Junior
    • 2
  • Felipe José Fernadez Coimbra
    • 2
  • Maria Dirlei Ferreira de Souza Begnami
    • 3
  • Rachel P. Riechelmann
    • 1
  • Victor Hugo Fonseca de Jesus
    • 1
  • Celso Abdon Lopes de Mello
    • 1
  1. 1.Medical Oncology DepartmentAC Camargo Cancer CenterLiberdadeBrazil
  2. 2.Surgical Oncology DepartamentAC Camargo Cancer CenterSão PauloBrazil
  3. 3.Pathology DepartamentAC Camargo Cancer CenterSão PauloBrazil

Personalised recommendations